Table 4.
Characteristics | Last visit with CS + MPAA treatment | End of follow-up |
---|---|---|
eGFR (mL/min/1.73 m2), median (IQR) | 64.0 (38.4–90.0) | 54.0 (19.0–80.0)* |
Proteinuria (g/day), median (IQR) | 0.6 (0.3–1.1) | 0.7 (0.3–1.5) |
Patients with haematuria, n (%) | 12 (57.1) | 14 (66.7) |
*P = 0.002.